Cystic Fibrosis Foundation issued the following clinical trial alerts on January 4, 2021. Note, although two of the trials have the same title, they apply to different age groups.
Phase 2 study of JBT-101 in people with CF
Status: Completed with results
Description: This study evaluated the safety and effectiveness of the anti-inflammatory drug JBT-101 (lenabasum), as well as how the body processes the drug, in adults with CF.
Age: 18 Years to 65 Years
Mutation: No Mutation Requirement
Fev1% Predicted: 40% or greater
Number of Visits: 8
Length of Participation: 127 days
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02465450
Phase 2 study of JBT-101 in people with CF
Status: Completed with results
Description: This study evaluated the safety and effectiveness of the anti-inflammatory drug JBT-101 (lenabasum), as well as how the body processes the drug, in adults with CF.
Age: 12 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 40 to 100%
Number of Visits: 10
Length of Participation: 32 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03451045
TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF
Status: Completed with results
Description: This study evaluated the effect of adding oral azithromycin to inhaled tobramycin in people with CF who are chronically infected with P. aeruginosa.
Age: 12 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 25 to 100%
Number of Visits: 5
Length of Participation: 14 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02677701